We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Toxicity evaluation of ifosfamide nanostructured lipid carriers designed for oral delivery in Wistar albino rats.
- Authors
Velmurugan, Ramaiyan; Nair, Keerthi G. S.
- Abstract
Aim: Ifosfamide nephrotoxicity is a serious adverse effect for one who undergoes cancer chemotherapy. Ifosfamide when administered orally as nanoparticles expected to minimize the ifosfamide-induced nephrotoxicity at a clinically relevant concentration. To further validate this expectation, an animal model of ifosfamide-induced nephrotoxicity was used to determine the protective effect of ifosfamide-loaded nanostructured lipid carriers when administered orally. Materials and Methods: Adult male and female Wistar albino rats were subjected to acute and subacute toxicity studies administering orally with ifosfamide-loaded nanostructured lipid carrier. Wister albino rats of either sex were administered with 0.5 ml of the vehicle, ifosfamide injection at a dose of 50 mg/kg body weight, and ifosfamide NLC orally at doses of 50 and 100 mg/kg body weight. Toxic manifestations and mortality were monitored daily. Both the serum and urine biochemical parameters and hematological parameters were determined using standardized laboratory method. Results: There was no mortality, or any signs of behavioral changes or toxicity observed after oral administration of ifosfamide NLC up to the dose level of 150 mg/kg body weight in rats. Ifosfamide NLCs, when administered orally, markedly reduce the severity of renal dysfunction induced by ifosfamide with a significant decrease in elevations of serum creatinine (47.82 ± 2.25 vs. 32.64 ± 1.28 mmol l - 1) as well as a reduced elevation of ß2-microglobulin excretion (25.54 ± 122 vs. 19.86 ± 1.22 nmol l - 1) and magnesium excretion (19.62 ± 1.56 vs. 16.12 ± 1.22 mmol l - 1). Conclusion: Our results suggest a potential therapeutic role for ifosfamide when administered as nanoparticle minimizing ifosfamide nephrotoxicity.
- Subjects
IFOSFAMIDE; DRUG toxicity; ORAL drug administration; LABORATORY rats; DRUG delivery systems; CANCER chemotherapy
- Publication
Drug Invention Today, 2018, Vol 10, Issue 2, p192
- ISSN
0975-7619
- Publication type
Article